Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 0.79 |
| ▸ | FPR3 | P25089 | 1/20 | 0.77 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.77 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587148 | 1.00 | CCR1 (0.79) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL4587143 | 1.00 | CCR1 (0.79) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL4586612 | 1.00 | CCR1 (0.79) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL5972113 | 1.00 | CCR1 (0.79) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL4588309 | 0.92 | CCR1 (0.78) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL4588307 | 0.92 | CCR1 (0.78) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL4588312 | 0.92 | CCR1 (0.78) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL4588280 | 0.92 | CCR1 (0.75) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL4588285 | 0.92 | CCR1 (0.75) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL4588459 | 0.91 | CCR1 (0.79) | CCR1FPR3GPR65GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423166-A2 | NON-PEPTIDE CCR1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PROGRESSIVE RENAL FIBROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003013656-A2 | NON-PEPTIDE CCR1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PROGRESSIVE RENAL FIBROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-20 | — | — | WO | disclosed |